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Abstract 
Amphiphilic Janus-dendrimers are able to self-assemble into nanosized vesicles named 
dendrimersomes. We recently synthesized the 3,5-C12-EG-(OH)4 dendrimer that generates 
dendrimersomes with very promising safety and stability profiles, that can be loaded with different 
contrast agents for in vivo imaging. In this contribution, nanovesicles were loaded with both the 
Magnetic Resonance Imaging (MRI) reporter GdDOTAGA(C18)2 and the glucocorticoid drug 
Prednisolone Phosphate (PLP), in order to test their effective potential as theranostic nanocarriers 
on murine melanoma tumour models. The incorporation of GdDOTAGA(C18)2 into the membrane 
resulted in dendrimersomes with a high longitudinal relaxivity (r1 = 39.1 mM
-1
s
-1
, at 310 K and 40 
MHz) so that, after intravenous administration, T1-weighted MRI showed a consistent contrast 
enhancement in the tumour area. Furthermore, the nanovesicles encapsulated PLP with good 
efficiency and displayed anti-tumour activity both in vitro and in vivo, thus enabling their practical 
use for biomedical theranostic applications. 
Keywords 
Dendrimersomes, prednisolone phosphate, melanoma, theranostic, magnetic resonance imaging. 
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Introduction 
Despite the rapid advances in diagnostic and therapeutic protocols, cancer still remains one of the 
most challenging domains of investigation in modern medicine. The limitations or the failure of 
current treatments encouraged the research for innovative approaches to cancer disease, in the effort 
to improve the early-stage detection and specifically target the therapy.
1
  
By combining both therapeutic and diagnostic properties in one single platform, theranostic systems 
are emerging medical tools that hold great promises in enhancing the therapeutic outcome of cancer 
therapy.
2-5
 Unlike conventional approaches, the theranostics integrates specific molecular targeting, 
therapeutic activity, and imaging in one multifunctional medical system, very often based on the use 
of nanosized carriers. Some of the most attractive features of the nanoparticle-based theranostics 
include the opportunity to specifically deliver different pharmaceutically active molecules, to 
monitor their biodistribution in vivo, and, in some cases, also to control/trigger the release of the 
drug at the target site.
5,6
     
So far, a very wide and continuously extending array of nanoplatforms has been considered for 
biomedical applications, but few of them have received so much interest in the theranostic field as 
liposomes. These vesicles, composed of a phospholipidic bilayer, already proved their ability to 
load both imaging-responsive molecules and drugs, and to act as theranostic agents in several 
pathologic scenarios, especially in oncology.
5,7
  
Following the work on liposomes, other nanosized bilayered vesicular structures have been 
proposed. Among them, dendrimersomes (DSs) are vesicles self-assembled from amphiphilic 
Janus-dendrimers, described for the first time by Percec et al. in 2010.
8 
Based on these initial 
studies, we argued whether DSs could be employed as reliable alternative to liposomes in the 
advanced biomedical protocols, especially considering the advantages in terms of cost and easiness 
of synthesis of the dendrimeric constituents of the membrane. Therefore, we initially evaluated the 
potential of these nanocarriers to act as MRI agents by loading paramagnetic Gd-complexes either 
in the aqueous core or in the membrane of the particles.
9-11
 Furthermore, we recently synthesized a 
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new low generation Janus-dendrimer (3,5-C12-EG-(OH)4, Chart 1, left) that has been demonstrated 
to form Gd-loaded dendrimersomes of high stability and biocompatibility.
10
 
In this contribution, we report on the first in vivo testing of the theranostic potential of DSs 
composed of the 3,5-C12-EG-(OH)4 dendrimer, co-loaded with a drug (Prednisolone Phosphate, 
PLP, Chart 1) and the lipophilic MRI agent GdDOTAGA(C18)2 (Chart 1), whose excellent MRI 
performance has been very recently demonstrated.
11
  Since liposomal formulations of PLP already 
proved to be effective in the treatment of melanoma,
12-18
 the herein investigated theranostic 
platform was tested in vivo on a syngeneic murine melanoma model and its therapeutic efficacy was 
compared to that provided by a corresponding liposome-based formulation. 
 
 
Chart 1. Structures of the dendrimersomes components. Left: 3,5-C12-EG-(OH)4 Janus dendrimer (main constituent 
of the dendrimersomes); middle: GdDOTAGA(C18)2 complex (MRI agent incorporated in the dendrimersome bilayer); 
right: prednisolone phosphate (PLP, antitumour drug encapsulated in the inner core of the dendrimersomes). 
 
Materials and methods 
Chemicals 
The phospholipids 1,2-distearoyl-sn-glycero-3 phosphoethanolamine-N-
[carboxy(polyethyleneglycol)-2000] ammonium salt (DSPE-PEG2000-COOH) and 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) were purchased from Avanti Polar Lipids Inc. 
(Alabaster, AL, USA). The 3,5-C12-EG-(OH)4 Janus dendrimer was synthesized as described 
elsewhere.
10
 Briefly, the amphiphile was obtained by linking the hydrophobic block 3,5 bis-dodecyl 
substituted benzoyl ether to a generation 1 of 2,2-bis(hydroxymethyl)propanoic acid, using  
ethylene glycol as spacer between the two moieties. The first synthesis intermediate, a 2-
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hydroxyethyl 3,5-(didodecyloxy)benzoate was obtained by reacting 3,5-(didodecyloxy)benzoic acid 
with an excess of ethylene glycol in the presence of 4-(dimethylamino)pyridinium p-
toluenesulfonate (DPTS) and dicyclohexylcarbodiimide (DCC). Following the same coupling 
procedure, 2,2,5-trimethyl-1,3-dioxane-5-carboxylic acid was reacted with the free hydroxyl group 
of the first synthesis intermediate. Deprotection of the acetonide was carried out in a 1:1 mixture of 
6 M HCl and THF to get a generation zero intermediate. The final compound was obtained by 
repeating once again the coupling and the deprotection steps. 
GdDOTAGA(C18)2
 
was synthesized in a four steps-process starting from the DOTAGA(tBu)4, as it 
was already reported in literature.
11
 Briefly, the free carboxylic acid of DOTAGA(tBu)4 was 
activated by formation of the N-hydroxysuccinimidyl ester, which was then reacted with 
dioctadecylamine in pyridine at 70°C. The free ligand was obtained after tBu esters deprotection 
using a 1:1 mixture of TFA and dichloromethane and the Gd(III) complex was prepared by reacting 
the ligand with GdCl3 in methanol at 50°C overnight. All other chemicals and reagents were 
purchased from Sigma-Aldrich (St. Louis, USA), and used as received unless otherwise noted. 
Nanovesicles preparation 
DSs and liposomes were prepared by the thin film hydration method.
19
 Briefly, to prepare the stock 
samples with a concentration of 80 mg/ml in the final vesicle suspension useful to perform further 
experiments, the appropriate amounts of amphiphilic materials GdDOTAGA(C18)2, DSPE-
PEG2000-COOH, and 3,5-C12-EG-(OH)4 dendrimer (or the phospholipid DPPC) were weighted 
according to the molar ratio 20:5:75, and then dissolved into chloroform (8 ml). After dissolution, 
the organic solvent was slowly evaporated, so that the amphiphilic components distributed in a thin 
homogeneous film at the bottom of a round flask. After two hours under vacuum, the film was 
hydrated at 50°C with an isotonic buffered solution containing PLP at 50 mg/ml, in addition to 
NaCl and 4-(2-hydroxyethyl)-1- piperazineethanesulfonic acid (HEPES) with a final whole 
osmolarity of ca. 300 mOsm and pH of 7.4. The vesicular suspension was then extruded several 
times through polycarbonate filters (Lipex extruder, Northern Lipids Inc.) with pore diameters 
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decreasing from 1 μm to 200 nm. Finally, to completely remove the non-encapsulated drug, an 
exhaustive dialysis was carried out at 4°C against an isotonic buffer consisting of a pH 7.4 solution 
0.15 M of NaCl and 0.004 of M 4-(2-hydroxyethyl)-1- piperazineethanesulfonic acid (HEPES), in a 
total volume of 2 L and for a minimal duration of 16 hours, with one buffer renewal after the first 4 
hours. 
Nanovesicles characterization 
The mean hydrodynamic diameter and the polydispersity of the vesicles were determined by 
Dynamic Light Scattering (DLS, Zetasizer Nano 90 ZS, Malvern, UK).  
The relaxometric characterization of GdDOTAGA(C18)2-bearing nanoformulations was carried out 
to define the longitudinal relaxivity r1 (at 25°C and 37°C) as a function of the applied magnetic 
field. Specific details about such measurements are available on the Electronic Supplementary 
Information (ESI). The total concentration of Gd in the samples was determined by a relaxometric 
measurement (at 20 MHz) after mineralization. Briefly, the samples were diluted 1:2 with 
concentrated HCl (37%) and stored overnight at high temperature (120°C) in a sealed glass 
ampoule to ensure the complete release of the metal ions from the complexes and to obtain free 
Gd(III) aqua-ions. The R1
obs
 measurement (at 25°C) allowed for the accurate estimation of the Gd 
concentration through a calibration line obtained by using standard solutions of GdCl3.  
The total amount of PLP loaded into the vesicles was measured by analytical high-performance 
liquid chromatography (HPLC), carried out on a Waters Alliance System (separations module: 2695 
model) equipped with a photodiode array detector (model 2998) and a Waters Atlantis C18 reverse 
phase column (4.6 mm x 150mm, 3.5µm). The chromatographic separation took 37 minutes in 
gradient mode, with a re-equilibration time of 18 min to restore the initial conditions. Gradient 
composition started from 95% of A (H2O containing 0.1% Trifluoro Acetic Acid, TFA)-5% of B 
(CH3CN added with 0.1% TFA) and it was maintained for 2.5 min. Then, B was raised to 30% at 15 
min, 60% at 30 min, and finally 100% at 35 min remaining until the end of the analysis. The total 
amount of PLP in the vesicular suspension (5 mg of amphiphilic material per mL of hydration 
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solution) was quantified by monitoring the eluate through UV detection (detection wavelengths set 
between 200 and 400 nm). The drug quantification was performed at λ=278nm.20 In order to 
determine the drug-loading efficiency of the nanocarriers, the PLP content of samples was then 
compared to the initial amount of PLP present in the hydration solution (0.103 M).  
Cells 
All cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) 
and resulted negative for mycoplasma test (MycoAlert
TM
 Mycoplasma Detection Kit, Lonza Sales 
AG, Verviers, Belgium). Murine fibroblasts (NIH/3T3), melanoma (B16.F10) and human umbilical 
vein endothelial (HUVEC) cells were cultured as monolayers at 37°C in a 5% CO2-containing 
humidified atmosphere in Dulbecco’s modified Eagle’s medium (DMEM). The medium was 
supplemented with 10% (v/v) of heat-inactivated foetal bovine serum, 2 mM of Glutamine, 100 
U/ml of penicillin and 100 μg/ml of streptomycin. At 80% confluency, cells were trypsinized with 
0.01% trypsin and 0.02% EDTA in Phosphate-buffered Saline (PBS). All cells employed for 
cellular tests were at passages included between 5 and 10. Culture medium, fetal bovine serum, 
penicillin-streptomycin mixture and trypsin were all purchased from Lonza (Lonza Sales AG, 
Verviers, Belgium). 
Cell viability assessment 
Cell viability was assessed on murine fibroblasts (NIH/3T3), melanoma (B16.F10) and human 
umbilical vein endothelial (HUVEC) cells after incubation with the paramagnetic dendrimersomes 
(Gd-DS), PLP-loaded paramagnetic dendrimersomes (PLP-Gd-DS) or liposomes (PLP-Gd-LIPO), 
and free PLP, after 1, 6 or 24 h incubation. The selected doses of PLP and amphiphilic material 
were 1 and 40 mg/ml respectively, in all experiments. Before being added to cell culture, vesicles or 
free PLP were diluted into culture medium to achieve the desired concentration and filtered by 
sterile 0.4 μm filters. The viability was assessed by a fluorimetric assay based on the cell metabolic 
activity (CellTiter-Blue® Cell Viability assay, Promega, Madison, USA). The CellTiter-Blue® 
reagent contains the indicator dye Resazurin that is reduced to highly fluorescent Resofurin by 
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viable cells retaining metabolic capacities, so that the fluorescent signal generated from the assay is 
proportional to the number of living cells in the sample. Briefly, NIH/3T3, HUVEC and B16.F10 
cells were plated in 96-well multiwell plate at a concentration of 1.0×10
4
, 1.0×10
4
 and 5.0×10
3
 cells 
per well, respectively. After 24 h, cells were exposed to the incubation medium for 1, 6 and 24 h. 
Next, the incubation medium was removed and wells were washed three times with sterile PBS 
(200 µl). The CellTiter-Blue® reagent was added following manufacturer’s instructions (20 μl of 
reagent diluted 1:5 into culture medium for each well). After 4 h, supernatants were collected and 
placed in a black 96-well multiwell plate for fluorescence detection (excitation wavelength: 530-
560 nm, emission wavelength: 590 nm). Five independent experiments were performed to test each 
single condition, with cells plated in triplicate and fluorescence measurements repeated three times. 
The reported results represent the mean ± SD of the percentage of viable cells, normalized with 
respect to the control samples obtained by incubating cells with PBS-containing medium. 
Animals 
Eight weeks old female C57/BL6 mice with similar weight (around 20-21 g) were used for the in 
vivo tests, with at least eight animals per condition in all performed experiments. All mice involved 
in the study were obtained from Charles River Laboratories (Calco, LC, Italy) and maintained in 
standard housing conditions, with water and standard rodent chow ad libitum and 12 h light/dark 
cycle. Animal manipulation and all experimental procedures were performed in accordance with the 
European Community guidelines and approved by the Italian Ministry of Health.  
In vivo MRI experiments 
The performance of the theranostic probes was investigated in mice bearing a syngeneic xenograft 
B16 melanoma tumour. Tumours were generated by subcutaneous injection of 2.5×10
5 
melanoma 
cells (in 150 l of PBS) on the flank of the animal. After 10 days, mice developed solid tumours of 
2-4 mm in diameter, and were ready to begin the treatment and the imaging procedures. For the 
MRI experiments, mice were anesthetized by intramuscular injection of a combination of 
tiletamine/zolazepam (zoletil 100; Virbac, Milan, Italy) 20 mg/kg and xylazine (Rompum; Bayer, 
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Milan, Italy) 5 mg/kg. Animals were administered via tail vein injection with PLP-Gd-DS or PLP-
Gd-LIPO, receiving 0.04 mmol/kg of Gd(III) and 10 mg/kg of drug. Control experiments were 
carried out by injecting the paramagnetic dendrimersomes (Gd-DS). As shown in Scheme 1, the 
administration was repeated twice over a time range of 2 weeks: at day 0 (corresponding to the 
tenth day after tumour inoculation) and at day 7. MRI was carried out immediately before, 
immediately after, and 1, 2, 4 and 6 days after each injection. An additional image acquisition was 
performed 6 h after the second administration.  
 
Scheme 1. Flowchart of the theranostic study. After tumour cells were subcutaneously inoculated, a time range of ten 
days was required for the tumour to develop. The nanoformulations loaded with Gd-DOTAGA(C18)2 and PLP were 
injected at day 0 and day 7. MRI was carried out immediately before, immediately after and 24, 48, 96 and 144 h after 
each injection. An additional image acquisition was performed 6 h after the second administration. Finally, at day 15 
animals were sacrificed.  
Images were acquired on a 1 T MRI Scanner (Aspect M2 High Performance System, Aspect 
Magnet Technologies Ldt, Letanya, Israel), consisting of NdFeB Magnet equipped with a solenoid 
Tx/Tr coil of inner diameter of 35 mm. The system is equipped with a fast gradient (gradient 
strength 450 mT m
-1
 at 60 A, ramp time 250 µs at 160 µV), with a field homogeneity of 0.2-0.5 
gauss. To evaluate the imaging performance of DSs, T1-weighted images (T1w-images) were 
acquired by using a standard spin echo sequence, setting the following parameters: TR = 250 ms, 
TE = 8.9 ms, matrix size = 128 × 128, slice thickness = 1.5 mm, NA = 8, FOV = 35 mm. The Mean 
Signal Intensity (SI0) was calculated on T1w-images by manually drawing regions of interest (ROIs), 
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and then it was normalized with respect to the signal calculated on a glass tube containing 0.5 mM 
of Gadoteridol in aqueous solution, that was used as an external reference during image acquisition. 
The resulting value was the Normalized Signal Intensity, SIn. The T1 contrast enhancement (T1
Enh
) 
was calculated from the normalized signal intensity values measured after the injection of the 
theranostic agent (SIn
POST
), after subtraction of the corresponding value measured before the 
injection (SIn
PRE
):  
 
Multislice T2-weighted images were acquired by using a Fast Spin Echo sequence set with the 
following parameters: TR = 2500 ms, TE = 49.4 ms, matrix size = 160 × 152, slice thickness = 1.5 
mm, NA = 6, FOV = 40 mm. The tumour volume was determined by accurately drawing a ROI 
along the perimeter of the lesion in each T2w-image, and by simply adding all slice volumes. The 
tumour growth was monitored for 15 days, and then the blood and the urine were sampled 
immediately after the final MRI acquisition. Finally, the animals were sacrificed and their organs 
(kidney, liver, spleen, muscle, heart, lung, and tumour) were explanted. In a special cohort of 
animals (n=8 per condition), the sampling of blood and urine, and the organ explant were performed 
on day 7, without providing the second administration of PLP-nanovesicles. The content of Gd(III) 
in the various tissues was measured by the inductively coupled plasma mass spectrometry (ICP-
MS) after digestion. Briefly, the volume of blood and urine samples and the weights of all organs 
were registered. Blood samples were added with heparin (20 l) in order to avoid clotting and allow 
a precise quantification of the collected volume. Then, all biological specimens were treated with 
concentrated HNO3 (70%) and digested by applying microwave heating (Milestone MicroSYNTH, 
Microwave labstation equipped with an optical fiber temperature control and HPR-1000/6M six 
position high-pressure reactor, Bergamo, Italy). After digestion, the remaining material was diluted 
in ultrapure water (final volume of 3 mL) and further filtered with 0.2 μm filters. Finally, samples 
were analysed by ICP-MS (Thermo Scientific ELEMENT 2 ICP-MS -Finnigan, Rodano, Milano, 
T
1
Enh =
SI
n
POST - SI
n
PRE
SI
n
PRE
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Italy). For urines, the values of Gd(III) content were reported as metal concentration, whereas for 
organs they were expressed with respect to the organ mass. In case of blood, these values were 
finally reported as circulating metal concentration by calculating the Total Blood Volume (TBV) 
for each animal from the average value reported for mice (79 ml/kg).
20
  
Statistical analysis 
All data are presented as Mean Values ± Standard Deviation, unless noted otherwise. Significance 
of the differences among the experimental conditions was identified by applying the Student t-test 
or ANOVA test, as indicated. 
 
Results  
In vitro characterization 
By hydrating the amphiphilic films (GdDOTAGA(C18)2, DSPE-PEG2000-COOH, and 3,5-C12-EG-
(OH)4 in molar ratio 20:5:75) with an isotonic PLP-containing solution, vesicles with favourable 
physico-chemical properties for in vivo experiments were obtained. The suspensions were found to 
show a good dimensional uniformity (PDI values < 0.2) and a mean hydrodynamic diameter of 
around 150 nm (Table S1, ESI). As  previously reported,
10
 the incorporation of the paramagnetic 
GdDOTAGA(C18)2 complex provided vesicles with high proton relaxivity, achieving values of r1 
around 39.1 mM
-1
 s
-1
 at 40 MHz and 310 K (Table S2 and Figure S1, ESI). Liposomes with a 
membrane composition analogue to DS in which DPPS replaced the 3,5-C12-EG-(OH)4 dendrimer 
showed similar characteristics, and were then chosen as control formulation in this study. The two 
nanoformulations displayed a similar PLP loading efficiency and were able to retain an almost 
equivalent fraction of PLP during the preparation (0.34 % and 0.29 % of total PLP present in the 
suspensions of DS and LIPO, respectively, when prepared at 5 mg/ml of amphiphilic materials).  
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Cytotoxicity 
The potential capability of the theranostic dendrimersomes to hinder the cancer progression was 
tested in vitro on several cell cultures (Figure 1).  
 
 
Figure 1. In vitro anti-tumour effects. Cell viability assessed by Resazurin/Resofurin assay on murine fibroblasts 
(NIH/3T3), melanoma (B16.F10) and human umbilical vein endothelial (HUVEC) cells after treatment with empty 
paramagnetic dendrimersomes (Gd-DS), paramagnetic PLP-loaded dendrimersomes (PLP-Gd-DS) or liposomes (PLP-
Gd-LIPO), and free PLP. Incubation times were 1 h (a), 6 h (b) or 24 h (c). In all the experiments, the amounts of PLP 
and dendrimeric material were 1 mg/mL and 40 mg/ml, respectively. Statistical significance addressed by ANOVA test 
(single and double asterisks indicating the p-value < 0.05 and 0.01, respectively). 
 
In order to assess either the direct anti-tumour or the anti-angiogenic effects, melanoma cells 
(B16.F10 line, also used to generate the in vivo model), and endothelial cells (HUVEC line) were 
incubated with the control drug-free paramagnetic dendrimersomes (Gd-DS), the paramagnetic 
PLP-loaded dendrimersomes (PLP-Gd-DS), the correspondent liposomes (PLP-Gd-LIPO), and free 
PLP for 1, 6 or 24 h at 37°C. A fibroblast cell line (NIH/3T3) was employed as a control to identify 
possible unspecific cytotoxicity effects. In all conditions, the incubation was carried out so as to 
always deliver the same dose of PLP to the cells, and thereafter the cell viability was assessed. For 
all cell lines, the addition of the simple paramagnetic dendrimersomes at any incubation time range 
did not affect viability, thus indicating no toxicity associated with the presence of the vehicle in the 
medium. The free PLP dissolved into the medium induced only mild cytotoxicity on control 
fibroblasts and melanoma cells, with slightly more evident effects on melanoma cells at longer 
incubation times. However, the free PLP dramatically affected the endothelial cell viability, which 
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resulted severely impaired even at short incubation times (with a decrease of 20.9 % and 42.5 % 
after 1 and 6 h, respectively). After 1 h of incubation with the PLP-loaded nanosystems, only 
limited effects were observed: the maximum viability reduction (≈8.6%) was detected on 
endothelial cells after incubation with PLP-Gd-LIPO, but all other data collected under these 
experimental conditions did not substantially differ. After 6 h, the exposure to the nanosystems 
began to induce a stronger cytotoxicity on HUVECs and, though to a minor extent, also on B16.F10 
cells. Interestingly, in both cases a statistically relevant difference (p-value < 0.01 and 0.05 for 
endothelial and melanoma cells, respectively) exists between the results obtained with PLP-Gd-DS 
and PLP-Gd-LIPO, with the latter showing a slightly higher effectiveness. Finally, for the longer 
incubation time (24 h), the efficacy of the two nanomedicines was almost equivalent, even if it 
varied depending on the tested cell line, being the endothelial and melanoma cell viability reduced 
to 40% and 85%, respectively. Importantly, in these conditions the treatment with the PLP-
nanosystems always matched the results observed with the use of free PLP. Finally, it is arguable 
that some unspecific phenomena of cytotoxicity also occurred, as shown by the decrease of the 
viable fibroblast number (10% of viability decrease for both encapsulated and free drug).     
In vivo MR imaging 
In vivo 1 T MRI performed on melanoma-bearing mice after intravenous administration of PLP-Gd-
DS revealed a consistent (ca. 50%) contrast enhancement (T1
Enh
) in the tumour area (Figure 2 and 
Figure 3) immediately after the first injection (day 0).  
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Figure 2. T1 contrast enhancement (T1
Enh
). Time evolution of the percentage T1 contrast enhancement (T1
ENH
) 
calculated on T1w-images of tumour, muscle, liver and spleen after the systemic administration of PLP-loaded 
dendrimersomes (black squares) and liposomes (gray circles) bearing the Gd-complex GdDOTAGA(C18)2. The time 
evolution of T1
ENH
 observed on muscular tissue is reported as a negative control. The injections were performed at day 0 
and day 7, respecting a dose of 0.04 mmol Gd/kg and 10 mg PLP/kg/week. 
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Figure 3.  Representative MR images. Representative axial T1w-images showing the evolution of T1 contrast over 15 
days of MRI monitoring on liver (top), spleen (middle), and tumour (bottom) after the administration of Gd-PLP-DS. 
 
As previously observed,
10,14 
the intratumour distribution of the contrast-enhanced areas appeared 
inhomogeneous, possibly reflecting local differences in the vascularization, which could affect the 
vesicular extravasation and the subsequent distribution of the contrast agents. After 24 h a similar 
T1
Enh
 value (51.2%) was still calculated, whereas in the following days the contrast progressively 
decreased (T1
Enh
 ≈ 30.7% at day 7). After the second administration, the T1
ENH
 values followed 
again a similar trend, remaining stable for about 24 h and then declining progressively. Also the 
control PLP-Gd-LIPO displayed an equivalent ability to produce a positive signal in the tumour 
without any relevant difference in the time evolution of the contrast. Moreover, whereas in the 
muscular tissue no remarkable contrast enhancement was detected, the spleen and the liver showed 
substantial T1
Enh
 values that persisted for several days after the injection of both theranostic agents. 
This indicates the accumulation of the nanosystems in the macrophage-rich organs of the 
mononuclear phagocyte system (MPS). Furthermore, the imaging data obtained with PLP-Gd-DS 
show a good accordance with previous studies, where only a single administration of Gd-DS (0.05 
mmol Gd/kg) was performed.
10
 Interestingly, after the second injection, the contrast in the liver 
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increased over time, similarly to what has been recently reported in mice treated with liposomes 
loaded with Gadoteridol and Doxorubicin.
21
 Finally, the organs belonging to the excretory system 
(kidneys and bladder, Figure S2) were highlighted by a T1-contrast increase only immediately after 
the injection (bolus passage), thus excluding the renal filtration of the paramagnetic probe and 
confirming the good in vivo stability of the theranostic nanoparticles.   
In vivo therapeutic effect 
During the imaging sessions, anatomical T2w-images were also acquired to assess the tumour 
volumes and monitor the disease progression (Figure S3), thus enabling the evaluation of the 
effects of the drug transported by the nanocarriers and their overall therapeutic validity (Figure 4). 
Both PLP-loaded dendrimersomes and liposomes were capable of delaying the tumour progression 
with respect to the case of untreated animals. The two nanoformulations induced clear and 
statistically relevant therapeutic effects only by day 8 (Table S3), determining a final decrease in 
the tumour growth rate of 39.1% and 32.4% for PLP-Gd-DS and PLP-Gd-LIPO respectively, at day 
15. At day 11 and 13, the increase in the tumour volume was slightly lower in mice receiving PLP-
Gd-DS than in those receiving PLP-Gd-LIPO (p-value < 0.05), whereas at the previous time points 
and at day 15 no substantial differences were detectable between the two groups.  
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Figure 4. Tumour growth and in vivo therapeutic effect. Time course of the tumour growth expressed as the 
percentage volume increase with respect to the initial tumour volume calculated at time 0 (20.4 ± 1.5 mm
3
), after the 
systemic administration of the control paramagnetic dendrimersomes (Gd-DS, white circles), the paramagnetic PLP-
loaded dendrimersomes (PLP-Gd-DS, black squares) or liposomes (PLP-Gd-LIPO, gray circles). Statistical significance 
addressed by ANOVA test (single and double asterisks indicating the p-value < 0.05 and 0.01, respectively).  
Dendrimersome biodistribution 
After the final MRI session (day 15), animals treated with PLP-Gd-DS were sacrificed to quantify 
the residual amount of Gadolinium in the different tissues (Figure 5). Organs and tumours were 
obtained also from a special additional cohort of diseased animals, which were sacrificed at day 7 
without receiving the second dose of the theranostic dendrimersomes. As expected, a considerable 
metal content was detected in the sites displaying the highest MRI contrast (spleen, liver and 
tumour), whereas in the other investigated organs (kidney, muscle, heart, and lung) the amount of 
Gd was negligible both at day 7 and 15. On the one hand, the amount of Gd found in liver and 
tumour at day 15 was approximately three times greater than that measured at day 7; on the other 
hand, in the same time interval the metal content in the spleen increased to a much lesser extent. In 
the urine and blood collected immediately before the sacrifice, a sub-micromolar amount of metal 
was detected, which almost doubled from day 7 to day 15. By considering that the concentration of 
the circulating Gd in a 19 g mouse at the moment of the first administration should approximately 
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correspond to 506.7 M under our experimental conditions, one could estimate that after 7 days the 
metal concentration in blood is dramatically reduced by a factor of ca. 1700. 
 
 
Figure 5. Residual gadolinium content in different tissues after the injection of PLP-Gd-DS. Amount of 
gadolinium normalized to the organ weight, measured by ICP-MS for different organs (liver, spleen, kidney, lung, 
muscle, and tumour) excised from mice at day 7 before the second administration of theranostic vesicles (left) or at day 
15 after the last MRI acquisition (center). Gadolinium concentration in the blood and the urine immediately before the 
animals were sacrificed at day 7 and 15 (right).  
 
Discussion 
Stimulated by the fact that dendrimersomes could represent a relevant alternative to liposomes by 
virtue of the lower cost and the easy synthetic approach of the starting materials,
10
 the aim of the 
present study was to investigate the MRI theranostic potential of drug-loaded DSs to treat cancer. 
The choice of the tumour model and the therapeutic strategy relied on the previously reported 
ability of liposomal PLP to inhibit the B16.F10 melanoma growth, possibly through a series of 
distinct mechanisms of action.
11-17
 The experimental conditions selected for the in vivo theranostic 
scheme, including the time for initial tumor development (10 days) and that dedicated to the MRI-
monitoring (15 days), were defined on the basis of previous works
11,22
 and pilot experiments carried 
out on B16.F10-derived melanoma models. Although limited, a time window of around 2 weeks 
already proved to be sufficient to monitor and assess the therapeutic efficacy of PLP encapsulated 
in long-circulating liposomes, showing that the tumor growth inhibition could be observed after a 
single intravenous injection of 20 mg/kg/week in mice bearing melanoma B16 or colon carcinoma 
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C26 xenografts.
23
 In previous investigations, our group demonstrated the value of MRI in 
monitoring the activity of paramagnetic liposomes for this type of application, providing accuracy 
in the assessment of the therapeutic response to melanoma cancer.
22
 As a natural consequence, in 
this study the results obtained for the DSs were compared to a standard liposomal formulation 
endowed with similar physico-chemical characteristics. Based on in vitro tests, liposomes and DSs 
share a similar ability to load the PLP during preparation, and when used on cell lines they do not 
determine significantly different consequences on the viability, except for a slight increase of the 
cytotoxicity observed in case of the 6 h-long exposition to the liposome formulation. However, after 
one day of incubation this divergence vanished, so that the effect produced by the two 
nanoformulations became again equivalent and matched the cytotoxicity induced by the free PLP. 
Even the in vivo performance of the two systems either in terms of imaging contrast or therapeutic 
efficacy almost overlapped. Indeed, only at late stages of the protocol (day 11 and 13) the PLP-Gd-
DS effectively provided some advantages in the anti-tumour efficacy as compared to the PLP-Gd-
LIPO, but at the end of the experimental monitoring (day 15) such a difference turned out to be not 
statistical. Finally, the MRI contrast and the analytical quantification of gadolinium suggest a long 
lasting residence of the DSs into the tumour tissue and in the other accumulation sites commonly 
expected for nanoparticles, as spleen and liver. Particularly, an accumulation phenomenon was 
observed in the liver, possibly caused by the RES cell-mediated clearance of the nano-objects. This 
observation becomes more interesting when considering that, due to a reduced ability in producing 
pro-angiogenetic factors, the tumour-associated macrophages (TAMs) were already defined as 
crucial players in the biological response of B16.F10 melanoma to liposomal glucocorticoids.
13 
 It 
has to be mentioned that the latest studies downgraded again the role of TAMs, by underlying a 
broader spectrum of PLP activities which includes also alterations of the tumour vasculature and 
dropdown of the circulating white blood cells, probably limiting the infiltration of angiogenesis-
stimulating monocytes.
16,17
 Nevertheless, based on our results, the marked cytotoxic activity 
induced by the PLP-Gd-DS and control liposomes on endothelial cells may support the previous 
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data identifying the inhibition of the angiogenetic process as one of the leading therapeutic routes. 
Furthermore, the long-term retention of the nanoprobes in the RES-organs may raise reasonable 
safety concerns around the real biological applicability of this strategy, considering the potential 
PLP-induced toxicity towards hepatic and splenic tissue. In fact, even if rare, the occurrence of 
corticosteroid-induced acute liver injury has been already described in the literature.
24
 However, 
since the liposomal encapsulation makes more effective the drug delivery, the PLP carried by 
nanovectors is generally administrated at low dosages and well tolerated in vivo.
12,25 
In our 
experimental conditions, neither effects of acute toxicity were ever noticed on living animals during 
the monitoring time, nor gross alterations (such as infarct, necrosis, vacuolation) could be identified 
in the structure or morphology of the organs by visual inspection after extraction for the post-
mortem Gd quantification. Moreover, the intravital destiny of PLP after nanovectors-mediated 
uptake by the RES still has to be clarified in order to understand if the long-term MRI signal in liver 
and spleen could be ascribed to Gd-label deposition only,
22
 being thus not indicative of the drug 
presence. This issue and the potential side effects derived from non-specific PLP accumulation will 
be the objects for future research. Encouragingly in this perspective, a PLP liposomal formulation 
has been recently produced according to GMP qualitative standards, and may be readily used in 
humans subjects, as it turn out to be characterized by a very promising safety profile with no 
specific evidence of PLP systemic accumulation.
26
  
 
Conclusions 
In summary, the herein reported results indicate that 3,5-C12-EG-(OH)4 Janus dendrimers, loaded 
with a suitable paramagnetic Gd(III) complex to ensure MRI detection, are capable of encapsulating 
PLP with efficiency and retention ability similar to conventional liposomes. Importantly, also the 
anti-tumour activity and the MR imaging performance of the dendrimersomes are quite 
comparable to those observed for the liposomal carrier. However, it is important to highlight that 
DSs have some advantageous over liposomes mainly related to the low cost and the easy synthetic 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
20 
 
approach of the membrane constituents. In conclusion, the present report definitively highlights the 
great potential of dendrimersomes as valuable and cheaper alternative to liposomes for 
nanovesicles-based biomedical applications. 
 
Acknowledgements 
This work was supported by the European Union, project INMiND [grant number 278850, 2012], 
and by Compagnia di San Paolo (CSP-2014 THERASIL Project). 
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
21 
 
References 
[1]. V. Sanna, N. Pala, M. Sechi, Targeted therapy using nanotechnology: focus on cancer, Int. J. 
Nanomed. 9 (2014) 467-83. 
[2]. M.F. Penet, B. Krishnamachary, Z. Chen, J. Jin, Z.M. Bhujwalla, Molecular imaging of the 
tumour microenvironment for precision medicine and theranostics, Adv. Cancer. Res. 124 
(2014) 235-56. 
[3]. S. Jeelani, R.C. Reddy, T. Maheswaran, G.S. Asokan, A. Dany, B. Anand, Theranostics: A 
treasured tailor for tomorrow, J. Pharm. Bioallied. Sci. 6 (2014) S6-8. 
[4]. K.M. Bennett, J. Jo, H. Cabral, R. Bakalova, I. Aoki, MR imaging techniques for nano-
pathophysiology and theranostics, Adv. Drug Deliv. Rev. 74 (2014) 75-94. 
[5]. M.S. Muthu, D.T. Leong, L. Mei, S.S. Feng, Nanotheranostics - application and further 
development of nanomedicine strategies for advanced theranostics, Theranostics 4 (2014) 
660-77. 
[6]. M.E. Caldorera-Moore, W.B. Liechty, N.A. Peppas, Responsive theranostic systems: 
integration of diagnostic imaging agents and responsive controlled release drug delivery 
carriers, Acc. Chem. Res. 44 (2011) 1061-70. 
[7]. B.T. Luk, R.H. Fang, L. Zhang, Lipid- and polymer-based nanostructures for cancer 
theranostics, Theranostics 2 (2012) 1117-26. 
[8]. V. Percec, D.A. Wilson, P. Leowanawat, C.J. Wilson, A.D. Hughes, M.S. Kaucher, D.A. 
Hammer, D.H. Levine, A.J. Kim, F.S. Bates, K.P. Davis, T.P. Lodge, M.L. Klein, R.H. 
DeVane, E. Aqad, B.M. Rosen, A.O. Argintaru, M.J. Sienkowska, K. Rissanen, S. Nummelin, 
J. Ropponen, Self-assembly of Janus dendrimers into uniform dendrimersomes and other 
complex architectures, Science 328 (2010) 1009-14. 
[9]. M. Filippi, J. Martinelli, G. Mulas, M. Ferraretto, E. Teirlinck, M. Botta, L. Tei, E. Terreno, 
Dendrimersomes: a new vesicular nano-platform for MR-molecular imaging applications, 
Chem. Commun. 50 (2014) 3453-3456. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
22 
 
[10]. M. Filippi, D. Patrucco, J. Martinelli, M. Botta, P. Castro-Hartmann, L. Tei, E. Terreno, 
Novel stable dendrimersome formulation for safe bioimaging applications, Nanoscale 7 
(2015) 12943-54. 
[11]. M. Filippi, D. Remotti, M. Botta, E. Terreno, L. Tei, GdDOTAGA(C18)2: an efficient 
amphiphilic Gd(III) chelate for the preparation of self-assembled high relaxivity MRI 
nanoprobes, Chem. Commun. (Camb). 51 (2015) 17455-8. 
[12]. R.M. Schiffelers, M. Banciu, J.M. Metselaar, G. Storm, Therapeutic application of long-
circulating liposomal glucocorticoids in auto-immune diseases and cancer, J. Liposome Res. 
16 (2006) 185-94. 
[13]. M. Banciu, R.M. Schiffelers, M.H. Fens, J.M. Metselaar, G. Storm, Anti-angiogenic effects of 
liposomal prednisolone phosphate on B16 melanoma in mice, J. Control. Release 113 (2006) 
1-8. 
[14]. M. Banciu, J.M. Metselaar, R.M. Schiffelers, G. Storm, Antitumour activity of liposomal 
prednisolone phosphate depends on the presence of functional tumour-associated 
macrophages in tumour tissue, Neoplasia 10 (2008) 108-17. 
[15]. M. Banciu, M.H. Fens, G. Storm, R.M. Schiffelers, Antitumour activity and tumour 
localization of liposomal glucocorticoids in B16 melanoma-bearing mice, J. Control. Release 
127 (2008) 131-6. 
[16]. M. Banciu, J.M. Metselaar, R.M. Schiffelers, G. Storm, Liposomal glucocorticoids as tumour-
targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice, J. Steroid. Biochem. 
Mol. Biol. 111 (2008) 101-10. 
[17]. E. Kluza, S.Y. Yeo, S. Schmid, D.W. van der Schaft, R.W. Boekhoven, R.M. Schiffelers, G. 
Storm, G.J. Strijkers, K. Nicolay, Anti-tumour activity of liposomal glucocorticoids: The 
relevance of liposome-mediated drug delivery, intratumoural localization and systemic 
activity, J. Control. Release 151 (2011) 10-7. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
23 
 
[18]. E. Kluza, M. Heisen, S. Schmid, D.W. van der Schaft, R.M. Schiffelers,  G. Storm, B.M. ter 
Haar Romeny, G.J. Strijkers, K. Nicolay, Multi-parametric assessment of the anti-angiogenic 
effects of liposomal glucocorticoids, Angiogenesis 14 (2011) 143-53. 
[19]. M.R. Mozafari, Liposomes: an overview of manufacturing techniques, Cell. Mol. Biol. Lett. 
(10) 2005, 711-9. 
[20]. B.M. Mitruka, H.M. Rawnsley, Clinical Biochemical and Haematological Reference Values 
in Normal Experimental Animals and Normal Humans, Mosby, New York, 1981. 
[21]. S. Rizzitelli, P. Giustetto, J.C. Cutrin, D. Delli Castelli, C. Boffa, M. Ruzza, V. Menchise, F. 
Molinari, S. Aime, E. Terreno, Sonosensitive theranostic liposomes for preclinical in vivo 
MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-
focused ultrasound, J. Control. Release 202 (2015) 21-30. 
[22]. E. Cittadino, M. Ferraretto, E. Torres, A. Maiocchi, B.J. Crielaard, T. Lammers, G. Storm, S. 
Aime, E. Terreno, MRI evaluation of the antitumour activity of paramagnetic liposomes 
loaded with prednisolone phosphate, Eur. J. Pharm. Sci. 45 (2012) 436-41. 
[23]. R.M. Schiffelers, J.M. Metselaar, M.H.A.M. Fens, A.P.C.A. Janssen, G. Meloma, G. Storm, 
Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in 
mice, Neoplasia. 7 (2005) 118–127. 
[24]. P. Carrier, B. Godet, S. Crepin, L. Magy, M. Debette-Gratien, B. Pillegand, J. Jacques, D. 
Sautereau, E. Vidal, F. Labrousse, G. Gondran, V. Loustaud-Ratti, Acute liver toxicity due to 
methylprednisolone: consider this diagnosis in the context of autoimmunity, Clin. Res. 
Hepatol. Gastroenterol. 37 (2013) 100-4.  
[25]. J.M. Metselaar, M.H. Wauben, J.P. Wagenaar-Hilbers, O.C. Boerman, G. Storm, Complete 
remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating 
liposomes, Arthritis Rheum. 48 (2003) 2059-66. 
[26]. M.E. Lobatto, C. Calcagno, M.J. Otten, A. Millon, S. Ramachandran, M.P. Paridaans, F.M. 
van der Valk, G. Storm, E.S. Stroes, Z.A. Fayad, W.J. Mulder, J.M. Metselaar, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
24 
 
Pharmaceutical development and preclinical evaluation of a GMP-grade anti-inflammatory 
nanotherapy, Nanomedicine. 11 (2015) 1133-40. 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
25 
 
Graphical abstract 
Dendrimersomes loaded with both the MRI reporter GdDOTAGA(C18)2 and the glucocorticoid drug 
Prednisolone Phosphate (PLP) displayed in vitro and in vivo efficacy in the treatment of murine 
melanoma. 
 
 
